कृपया अन्य खोज का प्रयास करें
TaiRx, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-711 that is used to treat secondary hyperparathyroidism; TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in patient’s blood Se level and immune system; and focuses on development of the nodal diagnostic devices and anti-body drugs. TaiRx, Inc. was founded in 2011 and is based in Taipei City, Taiwan.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Sheng-Chu Kuo | - | - | Director |
Jang-Yang Chang | - | - | Member of Scientific Advisory Committee |
Andrew Lin | - | - | Chairman of The Board |
Sarah Lee | - | - | Director |
Lucas Lin | - | - | Independent Director |
Yi-Wen Chu | - | - | Senior VP & Director |
Mary J.C. Hendrix | - | - | Member of Scientific Advisory Committee |
Tian-Shung Wu | - | - | Director |
Hsien-Shou Kuo | - | - | Independent Director |
Chia Hsiang Chang | - | - | Independent Director |
Harry M. Olson | - | - | Member of Scientific Advisory Committee |
Frank Shen | - | - | Director |
Chien Du-Shieng | - | - | Co-Founder, President, CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है